CD44 and neoplasm: Due to the growing body of literature utilizing CD44 as a marker of cancer cell stemness [71,72,73,74], we were somewhat surprised to find that time to tumor endpoint (2 cm3) in vivo did not differ between CD44 WT and KO conditions in either breast cancer cell line.